Uquifa — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Uquifa Group is a well-established, private European leader in the pharmaceutical CDMO and API manufacturing sector. With a 75-year history, it operates as a trusted partner for developing and manufacturing off-patent and specialty small molecule APIs, serving regulated markets worldwide. The company demonstrates a strong commitment to quality, evidenced by recent GMP certificate renewals, and to ESG principles, having achieved a Gold Medal from EcoVadis. Its business is built on a foundation of technical expertise, regulatory compliance, and a focus on employee development and sustainability.

Small Molecules

Technology Platform

Advanced chemical synthesis and process development for small molecule APIs, including scale-up, analytical development, and GMP manufacturing.

Opportunities

Growing demand for outsourced API manufacturing in Europe, driven by supply chain diversification needs.

The trend towards complex small molecules (e.g., HPAPIs) and the sustained market for off-patent generics present significant service opportunities.

Strong ESG credentials are a key differentiator in winning contracts.

Risk Factors

Exposure to regulatory non-compliance risks (GMP) that could halt production.

High competition in the CDMO sector may pressure pricing and margins.

Dependency on client projects and vulnerability to disruptions in the chemical supply chain.

Competitive Landscape

Uquifa competes in a fragmented but competitive global CDMO market, facing large players like Lonza and Siegfried, as well as numerous specialized and lower-cost regional manufacturers. Its differentiation is based on deep European regulatory expertise, a focus on quality and speed, a strong ESG profile, and a long operational history.

More companies in Small Molecule Drugs →More companies in Spain →